Aarkstore.com - Lung Cancer Vaccines- Pipeline_ Strategies and Clinical

							Aarkstore.com announces, a new market research report is available in its vast collection:


       Lung Cancer Vaccines: Pipeline, Strategies and Clinical
http://www.aarkstore.com/reports/Lung-Cancer-Vaccines-Pipeline-Strategies-and-Clinical-
157139.html

Summary

This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the
treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These
vaccines are directed at 24 antigens or antigen combinations.

Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new
cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year
survival rates are also low (15-20%) compared to other common cancers. In the US, studies have
shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs
(2005) were higher than for any other cancer.

Patient needs and the high burden of lung cancer drive the development of new therapies. While
improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and
targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently
required. Today, developments continue to be made in drug treatments for lung cancer; in
chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen
in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic
vaccines.

This Report

This report (see brochure) provides a comprehensive review of lung cancer vaccines and reviews R&D
and clinical developments in the treatment of lung cancer as the primary indication, as well as studies
that are evaluating lung cancer alongside other cancers.

Today, more than 40 candidate lung cancer vaccines are in development or being evaluated for the
treatment of lung cancer, most of which are already in clinical trials. This field is also showing
substantial innovation and 24 different antigen/multiple antigen targeting strategies are being
investigated. For the purpose of this report, multiple antigen targeting approaches have been treated
as single strategies. This report gives an overview of the status and clinical findings of these candidate
vaccines, and gives developmental and market-related perspectives in this rapidly developing field.

Key content:

• Late-stage (Phases 2/3, 3 and Approved, n = 5) pipeline vaccines and companies
• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) pipeline vaccines and companies
• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting
lung cancer, Phase 1, 1/2 and 2
• Antigens/antigen combinations being targeted by vaccines from preclinical through to Phase 3 and
Approved
• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of
therapeutic vaccines being evaluated for the treatment of lung cancer
• Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related
clinical responses) reported following clinical trials (Phase 1-3) of vaccines being evaluated for the
treatment of lung cancer
• Commercial partnerships and collaborations on pipeline therapeutic vaccines
• Drug combination strategies in the evaluation of therapeutic vaccines for the targeting of lung cancer
• A comprehensive listing of salient details of clinical trials of therapeutic vaccines being evaluated for
the treatment of lung cancer
• Technical and market insights and perspectives in the development and clinical evaluation of
therapeutic vaccines for the treatment of lung cancer
• Competitive and market-related information

Table of Contents:

Summary
1 Lung Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Lung Cancer Staging
1.4 Treatment of Lung Cancer
1.5 Survival Rates
1.6 Cost of Lung Cancer
1.7 New Developments
1.8 This Report
References

Chapter 2 Approved and Late-Stage Vaccines

Summary
2.1 Introduction
2.2 Overview
2.3 (One vaccine, Approved)
2.4 – 2.6 (Three vaccines, Phase 3)
2.7 (One vaccine, Phase 2/3)
References

Chapter 3 Early-Stage Vaccines

Summary

3.1 Introduction
3.2 Overview
3.3 – 3.12 (Ten vaccines, Phase 2)
3.13 – 3.22 (Ten vaccines, Phase 1/2)
3.23 – 3.37 (Fifteen vaccines, Phase 1)
3.38 – 3.39 (Two Vaccines, Preclinical)
References

More Related Reports :

 VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

 Biomarkers in Alzheimers Disease, 2011

 Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011

 Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011
 Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

 Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011

 Image-Based Biomarkers in Alzheimers Disease, 2011

 Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical

 Biomarkers in Parkinsons Disease, 2011

 Biomarkers in Breast Cancer, 2011


For More details about above & other Reports plz contact :

Vina

Aarkstore.com

Contact: Marketing team

Mob.No.918149852585

Email: enquiry@aarkstore.com

URL: http://www.aarkstore.com/

http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstore

http://www.aarkwebsolutions.com/

XML : http://www.aarkstore.com/feeds/Biopharmreports.xml